SCHEMBL475812

SCHEMBL475812

CON(C)C(=O)[C@@H](N)CCCNC(=N)N

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NOS3 P29474 1/20 0.38
NOS1 P29475 1/20 0.38
NOS2 P35228 1/20 0.38
NPY4R P50391 11/20 0.37
NPY1R P25929 6/20 0.37
DPP7 Q9UHL4 2/20 0.36
OTC P00480 1/20 0.36
NPY2R P49146 4/20 0.35
NPY5R Q15761 4/20 0.35
GNAI3 P08754 1/20 0.33
GNAO1 P09471 1/20 0.33
GNAI1 P63096 1/20 0.33
ALOX15 P16050 1/20 0.33
DDAH1 O94760 1/20 0.32
MEN1 O00255 1/20 0.32
CYP1A2 P05177 1/20 0.32
KMT2A Q03164 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19644274 1.00 NOS3 (0.38) NOS3NOS1NOS2NPY4RNPY1R
SCHEMBL27382578 0.84 NOS3 (0.41) NOS3NOS1NOS2NPY4RNPY1R
SCHEMBL9952947 0.84 NOS3 (0.41) NOS3NOS1NOS2NPY4RNPY1R
Hydrochloric Acid SCHEMBL8063762 0.83 NOS3 (0.41) NOS3NOS1NOS2NPY4RNPY1R
SCHEMBL2172217 0.80 NPY4R (0.45) NOS3NOS1NOS2NPY4RNPY1R
SCHEMBL42488 0.80 NPY4R (0.45) NOS3NOS1NOS2NPY4RNPY1R
SCHEMBL157856 0.80 NPY4R (0.45) NOS3NOS1NOS2NPY4RNPY1R
SCHEMBL18796571 0.79 DPP7 (0.41) NOS3NOS1NOS2NPY4RNPY1R
Hydrochloric Acid SCHEMBL2762373 0.78 NPY4R (0.44) NOS3NOS1NOS2NPY4RNPY1R
Hydrochloric Acid SCHEMBL940539 0.78 NPY4R (0.44) NOS3NOS1NOS2NPY4RNPY1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 325 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260055150-A1 GRAIL-1 PEPTIDE PRODUCTS AND METHODS UNIV MICHIGAN (US) 2026-02-26 US disclosed
EP-4680108-A1 PEPTIDE MULTIMER PRODUCTS AND METHODS The Regents of The University of Michigan (US) 2026-01-21 EP disclosed
US-20250263439-A1 HETERODIMERIC PEPTIDE REAGENTS AND METHODS THE REGENTS OF THE UNIVERSITY OF MICHIGAN 2025-08-21 US disclosed
EP-3660040-B1 INSULIN RECEPTOR PARTIAL AGONISTS MERCK SHARP & DOHME LLC (US) 2025-06-18 EP disclosed
EP-4565333-A2 GRAIL-1 PEPTIDE PRODUCTS AND METHODS Regents of the University of Michigan (US) 2025-06-11 EP disclosed
US-12269900-B2 Inhibitors of β integrin-G protein α subunit binding interactions THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2025-04-08 US disclosed
US-20250073355-A1 CD44-BINDING PEPTIDE REAGENTS AND METHODS REGENTS OF THE UNIVERSITY OF MICHIGAN 2025-03-06 US disclosed
US-20250051416-A1 INSULIN RECEPTOR PARTIAL AGONISTS MERCK SHARP & DOHME LLC (US) 2025-02-13 US disclosed
WO-2025006976-A2 MRNA DISPLAY LIBRARIES AND METHODS OF USE THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2025-01-02 WO disclosed
EP-3666792-B1 INSULIN RECEPTOR PARTIAL AGONISTS MERCK SHARP & DOHME LLC (US) 2024-12-18 EP disclosed
WO-2011075393-A2 GLUCAGON/GLP-1 RECEPTOR CO-AGONISTS INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2011-06-23 WO disclosed
EP-2307037-A1 GLUCAGON ANALOGS EXHIBITING ENHANCED SOLUBILITY AND STABILITY IN PHYSIOLOGICAL PH BUFFERS Indiana University Research and Technology Corporation (US) 2011-04-13 EP disclosed
EP-2300037-A2 GLUCAGON/GLP-1 RECEPTOR CO-AGONISTS Indiana University Research and Technology Corporation (US) 2011-03-30 EP disclosed
EP-2300035-A2 GIP-BASED MIXED AGONISTS FOR TREATMENT OF METABOLIC DISORDERS AND OBESITY Indiana University Research and Technology Corporation (US) 2011-03-30 EP disclosed
WO-2010148089-A1 GIP RECEPTOR-ACTIVE GLUCAGON COMPOUNDS INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2010-12-23 WO disclosed
WO-2010111617-A2 PARATHYROID HORMONE PEPTIDES AND PARATHYROID HORMONE-RELATED PROTEIN PEPTIDES AND METHODS OF USE VAN ANDEL RESEARCH INSTITUTE (US) 2010-09-30 WO disclosed
WO-2010071807-A1 AMIDE BASED GLUCAGON SUPERFAMILY PEPTIDE PRODRUGS INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2010-06-24 WO disclosed
WO-2010011439-A2 GIP-BASED MIXED AGONISTS FOR TREATMENT OF METABOLIC DISORDERS AND OBESITY INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2010-01-28 WO disclosed
WO-2009155258-A2 GLUCAGON/GLP-1 RECEPTOR CO-AGONISTS INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2009-12-23 WO disclosed
WO-2009155257-A1 GLUCAGON ANALOGS EXHIBITING ENHANCED SOLUBILITY AND STABILITY PHYSIOLOGICAL PH BUFFERS INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2009-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260055150-A1 GRAIL-1 PEPTIDE PRODUCTS AND METHODS TP53, TP53BP1, DDIT3 NOS3 2035/4885NOS1 1769/4885NOS2 3038/4885
US-20250263439-A1 HETERODIMERIC PEPTIDE REAGENTS AND METHODS ERBB2, EGFR, ERBB3 NOS3 4605/4885NOS1 4556/4885NOS2 4224/4885
US-20250051416-A1 INSULIN RECEPTOR PARTIAL AGONISTS INSR, GPR119, IRS1 NOS3 4268/4885NOS1 4464/4885NOS2 4370/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.